score: 3, Health, 2022-10-29 19:06:06, published by CNN
A monoclonal antibody treatment for Alzheimer's disease that showed promise in a Phase 3 trial may have contributed to a study participant's death, according to an adverse events report obtained by the digital health publication Stat. [additional details]
